IVDP-Hamburg
banner
ivdp-hamburg.bsky.social
IVDP-Hamburg
@ivdp-hamburg.bsky.social
The Institute for Health Services Research in Dermatology and Nursing (IVDP) at the University Medical Center Hamburg-Eppendorf (UKE) encompasses research in dermatology, health economics, patient outcomes, nursing and midwifery and provides clinical care.
Beim Deutschen Kongress für #Versorgungsforschung (#DKVF) 2025 in Hamburg hat Caroline Agricola für ihre Arbeit „Digitale Gesundheitskompetenz von angehenden #Hebammen - Ergebnisse einer Querschnittsstudie“ den 2. Posterpreis gewonnen. 🏆

👏 Herzlichen Glückwunsch zu dieser tollen Auszeichnung! 👏
November 2, 2025 at 8:52 PM
🎯How do student midwives want to work in the future?
Our study of 342 students in Northern Germany shows a clear preference: out-of-hospital birth care.

👉 pubmed.ncbi.nlm.nih.gov/40639811/

#midwive #birthCare #HealthServicesResearch #StudentMidwives
[Preparedness for professional practice and field preferences of student midwives in Germany] - PubMed
Student midwives are trained to provide care for women and their families. With academisation in 2019, theoretical education was transferred from vocational schools to institutions of higher education...
pubmed.ncbi.nlm.nih.gov
October 15, 2025 at 5:55 PM
🎯In 8,018 people with #psoriasis, biologic therapies required higher lab monitoring costs driven by age and comorbidities, yet these remain low relative to drug expenses. Initiation at specialized centers involves costly tests, while follow-up is far cheaper.

👉 pubmed.ncbi.nlm.nih.gov/40785802/
Utilization and Costs of Laboratory Monitoring in Biological and Non-Biological Psoriasis Treatment - Large-Scale Claims Data Analysis - PubMed
Biologic therapies for psoriasis induce considerably higher monitoring costs than non-biological systemic drugs. Age and CCI were main predictors for higher utilization of laboratory services, indicat...
pubmed.ncbi.nlm.nih.gov
September 29, 2025 at 7:49 PM
Reposted by IVDP-Hamburg
Our new systematic review shows that #MEcfs has significant economic consequences. None of the studies describe how many severely ill patients were included – probably very few. Therefore, the studies are likely to underestimate the burden.
link.springer.com/article/10.1...
Burden of Disease in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Scoping Review - Applied Health Economics and Health Policy
Objective Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious chronic and complex multi-system disease characterised by symptoms such as post-exertional malaise, fatigue, cognitive impairment and pain. Diagnosis is based on international consensus criteria, and no curative treatment is available. In the USA, its prevalence is estimated at 0.42% among adults, with women affected three times as often as men. Prevalence is expected to increase due to the COVID-19 pandemic. In addition to its severe symptoms, ME/CFS has a substantial economic impact. This scoping review aimed to systematically examine the global health, social and economic burden of ME/CFS. Methods We conducted a systematic literature search following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) guidelines in six databases and supplemented it with a citation search. We assessed study quality using a modified version of the Mixed Methods Appraisal Tool. Results We included 20 studies that assessed costs (n = 16), disability-adjusted life years (DALYs) (n = 3), employment rates (n = 1), and school attendance (n = 1) as indicators of disease burden. Reported costs per patient ranged from USD 2,916 to USD 119,611, with indirect costs accounting for the largest proportion. DALYs reported for the USA ranged from 0.714 million in 2016 to 5.77 million in 2022. Conclusion ME/CFS imposes a substantial health, social and economic burden of disease. Discrepancies in estimates are probably due to differences in study samples, methodologies, cost components, and healthcare systems. Because ME/CFS is assumed to be underdiagnosed, its true burden may be even higher.
link.springer.com
September 26, 2025 at 7:18 AM
New guidance on interpreting quality of life data in wound care!
We present:
👉 thresholds for the Wound-QoL questionnaire
👉 a quick-and-easy way to determine scores by counting top-box responses
🔗 pubmed.ncbi.nlm.nih.gov/40898606/

#wounds #ChronicWounds #HRQoL #QoL

@blomechristine.bsky.social
How to Interpret Quality of Life Assessment of Patients With Chronic Wounds Using the Wound-QoL - PubMed
The Wound-QoL assesses patients' health-related quality of life. Quick and valid interpretation of the results is crucial, but no thresholds have yet been established. Additionally, counting top box r...
pubmed.ncbi.nlm.nih.gov
September 23, 2025 at 6:59 AM
In Germany over 90% of patients with psoriatic arthritis received appropriate agents by dermatologists. Our analysis of 17,310 patients from the national psoriasis registry PsoBest underscores the need for targeted therapies addressing the systemic inflammation.
📌 pubmed.ncbi.nlm.nih.gov/40463331/
Are Systemic Drug Choices for Psoriasis by Dermatologists Compatible with Psoriatic Arthritis? Data from the German National Psoriasis Registry PsoBest - PubMed
Early and effective treatment of PsA is crucial to prevent persistent damage of the joints. Although most patients received recommended systemic treatment for PSO+PsA, there is a small number of patie...
pubmed.ncbi.nlm.nih.gov
September 5, 2025 at 11:14 AM
How does diet affect brain structure?
📌In a cohort conducted by the HCHS of 2652 adults, higher intake of vegetables, fruits and whole grains was linked to a healthier brain structure. The MIND diet, which focusses on brain health, showed the strongest association. pubmed.ncbi.nlm.nih.gov/40683131/
Exploring the relationship between dietary factors and structural brain alterations in a partial least squares correlation analysis - PubMed
Across all dietary patterns, vegetables and fruits were the food groups with consistent associations with preserved brain structure, indicating the importance of these foods for neurological health. T...
pubmed.ncbi.nlm.nih.gov
August 26, 2025 at 7:16 AM
How does tildrakizumab impact the well-being of people with #psoriasis and their families?
The POSITIVE study gathered real-world evidence in 9 European countries, showing its successful contribution to value-based long-term care for moderate-to-severe psoriasis.

pubmed.ncbi.nlm.nih.gov/36792337/
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study) - PubM...
ClinicalTrials.gov Identifier: NCT04823247 (Pre-results).
pubmed.ncbi.nlm.nih.gov
August 6, 2025 at 8:09 AM
How has #psoriasis treatment changed for people living with the condition in Germany?
Between 2010–2022, biological agent use rose by 450%❗, while per-person costs declined slightly. This shows how new treatments continue to reshape long-term psoriasis care.

👉 pubmed.ncbi.nlm.nih.gov/40600112/
Evolution of Drug Supply for Psoriasis from 2010 to 2022 - Real-World Claims Data Analysis in Germany - PubMed
In more than a decade, the use of innovative systemic drugs, especially biologicals, in Germany has increased substantially. Despite their high cost, biologic expenses per person have slightly decreas...
pubmed.ncbi.nlm.nih.gov
July 23, 2025 at 9:16 AM
Our new mixed-methods study reveals major barriers to #healthcare for patients with #alopecia areata in Germany: lack of reimbursement, limited access to systemic treatment, and gender and regional disparities.

Read our recommendations for action here:
👉 pubmed.ncbi.nlm.nih.gov/40447440/
June 17, 2025 at 11:44 AM
🔬 APPRECIATE study: A real-world analysis of #psoriasis patients evaluated the effects of apremilast, a phosphodiesterase-4 inhibitor, including those with genital involvement.
📌 Results showed improvements in disease severity and #QoL gains across all groups.

pubmed.ncbi.nlm.nih.gov/39969771/
Benefits and Satisfaction with Apremilast Treatment in Patients with Psoriasis Affecting the Genital Area: Secondary Analysis of the APPRECIATE Study - PubMed
The APPRECIATE study was registered at https://clinicaltrials.gov/ with the number NCT02740218.
pubmed.ncbi.nlm.nih.gov
March 31, 2025 at 8:11 AM
📝A recent case report describes the use of Ixekizumab, an IL-17A antagonist, in a patient with linear #psoriasis. The patient showed major improvement over 16 weeks. It highlights histological confirmation and explores IL-17 blockade as a therapeutic approach.

pubmed.ncbi.nlm.nih.gov/39866910/
Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report - PubMed
Linear psoriasis (LP) represents a rare variant of psoriasis. The clinical presentation includes erythematous plaques distributed along the Blaschko lines, reflecting the presence of embryological mos...
pubmed.ncbi.nlm.nih.gov
March 27, 2025 at 6:37 PM
👉💡New study links rising temperatures with increased heat-related #health issues in Germany. An analysis of health insurance data (2012-2021) shows Heat-related diagnosis spike in hotter months, highlighting urgent need for adaptation measures.
📌 #Climate #Heat

👉 pubmed.ncbi.nlm.nih.gov/39446174/
[Effects of high thermal stress on health-a nationwide analysis based on statutory health insurance routine data between 2012 and 2021] - PubMed
The article shows that associations between thermal stress and morbidity can also be found in routine SHI data. Against the background of an increase in high thermal stress due to climate change, this...
pubmed.ncbi.nlm.nih.gov
February 27, 2025 at 8:37 AM
📝👉Measuring the #patient perspective in Long COVID!

👏Many thanks to the Institute of Social Medicine and Health Systems Research in #Magdeburg, for inviting us to participate in this project!
#longcovid #Covid #SARS-CoV-2 #Research

@blomechristine.bsky.social

👉 pubmed.ncbi.nlm.nih.gov/39806627/
Patient-reported outcome measures for post-COVID-19 condition: a systematic review of instruments and measurement properties - PubMed
CRD42023391238.
pubmed.ncbi.nlm.nih.gov
February 19, 2025 at 2:28 PM
📌📝A study (2019-2021) with patients diagnosed with atopic dermatitis and undergoing GP treatment reveals that many patients experience poor outcomes. This could be due to both the rare use of modern therapies and the lack of participation in training programmes.
👉 pubmed.ncbi.nlm.nih.gov/39226528/
Healthcare of patients with atopic dermatitis by general practitioners - a nationwide survey in Germany - PubMed
A considerable proportion of patients with AD in GP care shows poor outcomes, as has been observed in dermatological care - possibly due to the lack of use of modern systemic therapy.
pubmed.ncbi.nlm.nih.gov
February 12, 2025 at 10:36 AM
👉Lime-induced phytophotodermatitis, triggered by lime juice and sun exposure, presents with #erythema, #pruritis, and #bullae. In our case report, despite treatment, residual hyperpigmentation persisted, emphasizing the importance of recognizing sensitizing agents.
pubmed.ncbi.nlm.nih.gov/39673137/
Palmate Erythema With Pruritus Following Contact With Lime Juice, a Variant of "Margarita Photodermatitis" - PubMed
Palmate Erythema With Pruritus Following Contact With Lime Juice, a Variant of "Margarita Photodermatitis"
pubmed.ncbi.nlm.nih.gov
February 6, 2025 at 6:43 AM
👉 Children with #psoriasis have different needs and less options for medical therapies than adults. Close #collaboration with pediatricians and other specialties for systemic therapies are crucial for a well-managed #health care and compliance. pubmed.ncbi.nlm.nih.gov/39518448/
#PediatricPsoriasis
Systemic Therapy of Psoriasis in Children-Proposal of an Algorithm for Interdisciplinary Teamwork - PubMed
<span><b>Background/Objectives:</b> Children and adolescents with psoriasis can have severe and long-lasting disease requiring early and effective therapy. The range of associated comorbidities is com...
pubmed.ncbi.nlm.nih.gov
February 3, 2025 at 8:20 PM
👏📊Prof. Dr. Kristian Reich has earned the title of Highly Cited Researcher by #Clarivate_Analytics, ranking him among the top 1% of his field from 2013 to 2023. His influential research on inflammatory #skin diseases and emerging treatment strategies is driving innovation in #dermatological #care.💪
January 18, 2025 at 6:13 PM
Preferences of patients with #malignant_melanoma to accept adjuvant therapy are based on treatment efficacy, side effects, and quality of life. Personalised approaches are essential for shared #decision-making.
👇🏽📄
pubmed.ncbi.nlm.nih.gov/39627632/
Preferences of melanoma patients to accept adjuvant therapy and toxicity - a qualitative substudy of the GerMelaTox-A project - PubMed
Patients in our study indicate high willingness to undergo adjuvant therapy, even when facing toxicity. The evaluation of potential side effects and prospects of treatment benefit is highly individual...
pubmed.ncbi.nlm.nih.gov
January 17, 2025 at 7:39 AM
🔍Wissenschaftliche:r Angestellte:r Junior (all genders) – Schwerpunkt "Statistik und Methodik" am UKE gesucht! 🔍

Werden Sie Teil unseres Teams!
👉 Bewerben Sie sich bis 27.01.2025!
👉 Details: uke.jobs/3961.
uke.jobs
January 10, 2025 at 10:02 AM
👉 #New: We developed and validated the Patient Benefit Index (PBI) for #Epilepsy - a novel tool measuring patients’ need, treatment benefits and challenges in epilepsy #care.
👉🏻📝 pubmed.ncbi.nlm.nih.gov/39612628/
January 9, 2025 at 1:57 PM
👉🏼Managing moderate-to-severe #psoriasis in women planning #pregnancy is challenging. Our study shows that TNF-alpha blockers are more often chosen following guidelines for treatment. Family planning needs communication between patient and doctor for decision-making. pubmed.ncbi.nlm.nih.gov/39555230/
Need for individualized counseling regarding psoriasis systemic therapy in women of childbearing age: analysis of the PsoFem study at the University Medical Center Hamburg - PubMed
For WoCBA with childbearing wishes, tumor necrosis factor alpha blockers were most frequently prescribed, in accordance with current guidelines/recommendations. Decision-making for continuing or chang...
pubmed.ncbi.nlm.nih.gov
December 10, 2024 at 8:13 AM
👉🏻📊Our large-scale data on late-onset #acne (acne tarda) in #Germany shows a relevant prevalence after adolescence, in particular in #women, resulting in about 950,000 involved. Specialised knowledge and health care for acne tarda and its comorbidities is needed📝
pubmed.ncbi.nlm.nih.gov/39422854/
Epidemiology and Healthcare of Juvenile and Late-Onset Acne: Claims Data Analysis - PubMed
Acne affects a relevant proportion of the German population not only in adolescence, and management of this inflammatory skin disease does not naturally follow medical guidelines or specialist recomme...
pubmed.ncbi.nlm.nih.gov
December 10, 2024 at 8:11 AM
📝People with visible skin conditions like #dermatitis, #psoriasis, #vitiligo, and #alopecia often face social and self-stigma. A new review explores factors behind this burden and highlights targets for psychosocial interventions.
#HealthAwareness 📄👇🏻
pubmed.ncbi.nlm.nih.gov/39247975/
Predictors and mechanisms of self-stigma in five chronic skin diseases: A systematic review - PubMed
Findings from the present review revealed several psychosocial variables that are malleable and potentially suitable as intervention targets. Those variables such as acceptance should be targeted in e...
pubmed.ncbi.nlm.nih.gov
November 28, 2024 at 12:52 PM